BEST-CLI注册研究中慢性肢体威胁性缺血患者的一年死亡率、心血管与肢体事件
BEST-CLI注册研究纳入40个中心的1009例慢性肢体威胁性缺血(CLTI)患者,报告1年结局:死亡25.6%,主要不良肢体事件(MALE)17.0%,MALE或死亡复合终点38.9%,主要不良心血管事件27.3%。黑人与白人、女性与男性间结局无差异。事件率高于BEST-CLI试验已发表数据。
要点
- CLTI患者1年死亡风险高,达25.6%,MALE或死亡复合终点达38.9%。
- 主要截肢率8.2%,任何血运重建率20.6%,主要不良心血管事件27.3%。
- 黑人与白人、女性与男性患者1年结局无差异。
核心结论
- 在包含不适合血运重建患者的CLTI大型多样队列中,1年死亡和肢体事件常见,且不因种族或性别而异。
- 患者临床事件率高于BEST-CLI试验已发表数据。
研究设计与样本
- BEST-CLI注册研究为前瞻性队列,2019至2023年从40个BEST-CLI试验中心纳入1009例CLTI患者。
- 女性占34.5%,黑人占28.1%,缺血性静息痛占62.8%,组织缺损占74.2%。
主要发现
- 1年MALE或死亡复合终点发生率为38.9%(95%CI 35.4%-42.7%)。
- MALE发生率为17.0%(95%CI 14.2%-20.4%),死亡率为25.6%(95%CI 22.3%-29.1%)。
- 主要截肢发生率为8.2%(95%CI 6.3%-10.7%),任何血运重建率为20.6%(95%CI 17.1%-24.8%)。
- 主要不良心血管事件发生率为27.3%(95%CI 23.9%-30.8%)。
- 黑人与白人患者、女性与男性患者之间结局无差异。
临床怎么用
- 应认识到CLTI患者1年内死亡和肢体事件风险高,加强心血管风险管理和肢体保护。
- 真实世界CLTI队列事件率高于BEST-CLI试验,临床决策需考虑患者人群差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with chronic limb-threatening ischemia (CLTI) are at risk for cardiovascular events, amputations, hospitalizations, and death. We aimed to describe 1-year outcomes in a broader, nonclinical trial cohort of patients with CLTI at a subset of Best Endovascular vs Best Surgical Therapy for Patients with Critical Limb Ischemia (BEST-CLI) trial sites. METHODS: The BEST-CLI Registry enrolled patients with CLTI from 40 BEST-CLI trial sites between 2019 and 2023. One-year rates of mortality, major adverse limb events (MALE), the composite of mortality or MALE, and major adverse cardiovascular events were reported and compared between key subgroups using multivariable analyses. RESULTS: Of 1009 patients who enrolled in the BEST-CLI Registry, 34.5% were female and 28.1% were Black. Ischemic rest pain was present in 62.8% of patients, and tissue loss in 74.2%. Over the course of a year, 38.9% of patients [95% confidence interval (CI), 35.4%-42.7%] experienced the composite of MALE or mortality; MALE occurred in 17.0% (95% CI, 14.2%-20.4%) and 25.6% died (95% CI, 22.3%-29.1%). Major amputation occurred in 8.2% (95% CI, 6.3%-10.7%) and 20.6% had any revascularization (95% CI, 17.1%-24.8%). Major adverse cardiovascular events occurred in 27.3% of participants (95% CI, 23.9%-30.8%). There were no differences in outcomes between Black and White patients or female and male patients. CONCLUSIONS: In this large, diverse cohort of patients with CLTI, including those ineligible for revascularization, mortality, and limb events were common at 1 year and did not differ based on race or sex. Patients had higher clinical event rates compared with those published in the BEST-CLI trial. Further work is needed to understand the generalizability of BEST-CLI findings to real-world cohorts of patients with CLTI.
引用
- Weissler EH, Li S, Shah NP, et al. One-year mortality, cardiovascular and limb events in the BEST-CLI Registry of patients with chronic limb-threatening ischemia. J Vasc Surg. 2026. PMID: 42749068. doi:10.1016/j.jvs.2026.08.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。